Qingdao Baheal Medical INC. (301015) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qingdao Baheal Medical INC. (301015) has a cash flow conversion efficiency ratio of 0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥230.38 Million ≈ $33.71 Million USD) by net assets (CN¥2.76 Billion ≈ $404.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Qingdao Baheal Medical INC. worth for the company's overall valuation and market capitalisation.
Qingdao Baheal Medical INC. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Qingdao Baheal Medical INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Qingdao Baheal Medical INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qingdao Baheal Medical INC. ranked by their cash flow conversion efficiency. Explore earnings quality score of Qingdao Baheal Medical INC. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CSSC Steel Structure Engineering Co Ltd
SHG:600072
|
-0.058x |
|
ANADOLU E.BIR.M. ADR 1/5
F:EF41
|
-0.001x |
|
AUB GROUP LTD.
F:A5H
|
N/A |
|
Systemair AB
ST:SYSR
|
0.029x |
|
Guangdong Ellington Electronics Technology Co Ltd
SHG:603328
|
0.053x |
|
SolarEdge Technologies Inc
NASDAQ:SEDG
|
0.059x |
|
ISC Co. Ltd
KQ:095340
|
0.030x |
|
Beijing Dabeinong Technology Group Co Ltd
SHE:002385
|
0.055x |
Annual Cash Flow Conversion Efficiency for Qingdao Baheal Medical INC. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Qingdao Baheal Medical INC. from 2018 to 2025. View latest Qingdao Baheal Medical INC. stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.74 Billion ≈ $401.22 Million |
CN¥934.45 Million ≈ $136.74 Million |
0.341x | +9.07% |
| 2024-12-31 | CN¥2.60 Billion ≈ $381.15 Million |
CN¥813.85 Million ≈ $119.09 Million |
0.312x | +21.91% |
| 2023-12-31 | CN¥3.12 Billion ≈ $456.47 Million |
CN¥799.50 Million ≈ $116.99 Million |
0.256x | +91.06% |
| 2022-12-31 | CN¥2.28 Billion ≈ $333.53 Million |
CN¥305.75 Million ≈ $44.74 Million |
0.134x | +60.87% |
| 2021-12-31 | CN¥2.17 Billion ≈ $318.14 Million |
CN¥181.30 Million ≈ $26.53 Million |
0.083x | +206.97% |
| 2020-12-31 | CN¥1.50 Billion ≈ $219.31 Million |
CN¥-116.83 Million ≈ $-17.10 Million |
-0.078x | -321.43% |
| 2019-12-31 | CN¥1.31 Billion ≈ $191.03 Million |
CN¥45.96 Million ≈ $6.73 Million |
0.035x | -31.18% |
| 2018-12-31 | CN¥1.08 Billion ≈ $158.76 Million |
CN¥55.50 Million ≈ $8.12 Million |
0.051x | -- |
About Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more